TESARO Inc (NASDAQ:TSRO) traded up 0% during trading on Friday . The stock traded as high as $59.41 and last traded at $58.89. 974,449 shares changed hands during trading, a decline of 25% from the average session volume of 1,299,344 shares. The stock had previously closed at $58.89.
Several equities research analysts have commented on the company. Robert W. Baird reiterated a “hold” rating and set a $120.00 price objective on shares of TESARO in a research note on Friday, November 10th. Leerink Swann upgraded TESARO from a “market perform” rating to an “outperform” rating in a research report on Wednesday, November 15th. Piper Jaffray Companies restated a “hold” rating and issued a $65.00 price target on shares of TESARO in a research report on Thursday, January 18th. HC Wainwright restated a “buy” rating and issued a $158.00 price target on shares of TESARO in a research report on Monday, November 20th. Finally, Barclays assumed coverage on TESARO in a research report on Monday, October 23rd. They issued an “equal weight” rating and a $135.00 price target for the company. Three equities research analysts have rated the stock with a sell rating, nine have given a hold rating, fourteen have assigned a buy rating and one has given a strong buy rating to the company. TESARO has a consensus rating of “Hold” and an average price target of $149.97.
The firm has a market cap of $3,370.00, a PE ratio of -6.99 and a beta of 1.25. The company has a quick ratio of 4.35, a current ratio of 4.73 and a debt-to-equity ratio of 0.34.
A number of institutional investors have recently modified their holdings of TSRO. Exane Derivatives purchased a new position in TESARO in the third quarter worth approximately $106,000. Toronto Dominion Bank grew its position in TESARO by 244.6% in the third quarter. Toronto Dominion Bank now owns 1,592 shares of the biopharmaceutical company’s stock worth $206,000 after acquiring an additional 1,130 shares during the period. Bourgeon Capital Management LLC purchased a new position in TESARO in the fourth quarter worth approximately $211,000. Fox Run Management L.L.C. acquired a new position in TESARO during the fourth quarter worth $218,000. Finally, Commonwealth Equity Services Inc acquired a new position in TESARO during the third quarter worth $222,000.
WARNING: “TESARO (TSRO) Trading 0% Higher” was posted by Community Financial News and is the sole property of of Community Financial News. If you are accessing this piece on another domain, it was illegally copied and reposted in violation of U.S. & international copyright legislation. The legal version of this piece can be viewed at https://www.com-unik.info/2018/02/11/tesaro-tsro-trading-0-higher.html.
TESARO, Inc is an oncology-focused biopharmaceutical company. The Company operates through the business of developing and commercializing of oncology-focused therapeutics segment. It is developing oncology-related product candidates, including rolapitant, niraparib and the product candidates under its immuno-oncology platform.
Receive News & Ratings for TESARO Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TESARO and related companies with MarketBeat.com's FREE daily email newsletter.